12:34:42 EST Tue 07 Dec 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Ademi LLP Investigates Claims of Securities Fraud against Revance Therapeutics, Inc.

2021-10-18 15:29 ET - News Release

MILWAUKEE, Oct. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Revance (NASDAQ: RVNC).  The investigation results from inaccurate statements Revance may have made regarding its business operations and prospects.

Click here to learn more about the investigation https://www.ademilaw.com/case/revance-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

The investigation focuses on Revance's disclosures regarding its manufacturing facilities. The FDA notified Revance that it would not approve an application for the use of DaxibotulinumtoxinA as an injectable treatment for moderate to severe frown lines, citing deficiencies related to the FDA's on-site inspection of Revance's manufacturing facility.  

If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, https://www.ademilaw.com/case/revance-therapeutics-inc.                    

We specialize in securities fraud and shareholder litigation.  For more information, please feel free to call us.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com

© 2021 Canjex Publishing Ltd. All rights reserved.